Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Phoenix, Arizona 85013


The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.


Inclusion Criteria: - At least 18 years old - Histologically confirmed diagnosis of malignant gliomas that requires systemic antineoplastic treatment. Malignant glioma is defined as any of the following: Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except low-grade glioma) - ECOG performance status score of 0, 1, or 2 - Each patient must sign a study-specific informed consent form Exclusion Criteria: Laboratory values of: - Absolute neutrophil count < 2000/µL - Platelet count < 100,000/µL - AST or ALT > 2 x the upper limit of normal (ULN) - Alkaline phosphatase > 5 x ULN - Bilirubin > 2 x ULN - Creatinine > 2.0 mg/µL and - Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during the study period - Women who are pregnant or lactating



Primary Contact:


Backup Contact:


Location Contact:

Phoenix, Arizona 85013
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.